$PBLA
Panbela Therapeutics, Inc. Stock $pbla

$pbla Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000143774924009418 Filed on March 26, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.204M	$931.0K	$5.033M
YoY Change	-10.95%	-45.07%	-16.73%
% of Gross Profit
Research & Development	$5.522M	$6.113M	$20.61M
YoY Change	57.41%	75.36%	-26.51%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$5.522M	$7.044M	$25.65M
YoY Change	57.41%	35.96%	-8.56%
Operating Profit	-$6.726M		-$25.65M
YoY Change	38.4%		-24.77%
Interest Expense	$63.00K	-$63.00K	-$194.0K
YoY Change	-38.24%	-64.41%	-167.36%
% of Operating Profit
Other Income/Expense, Net	-$532.0K	$614.0K	-$8.000K
YoY Change	110.28%	0.49%	-99.16%
Pretax Income	-$7.258M	-$6.493M	-$25.45M
YoY Change	41.95%	36.78%	-27.39%
Income Tax	-$138.0K	-$19.00K	-$186.0K
% Of Pretax Income
Net Earnings	-$7.100M	-$6.474M	-$25.26M
YoY Change	39.22%	36.73%	-27.61%
Net Earnings / Revenue
Basic Earnings Per Share	-$2.28		-$316.50
Diluted Earnings Per Share	-$2.28	-$27.16	-$232.40
COMMON SHARES
Basic Shares Outstanding	4.855M	5.128M	108.7K
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$262.0K	$2.578M	$2.578M
YoY Change	-95.0%	100.62%	100.62%
Cash & Equivalents	$262.0K	$2.578M	$2.578M
Short-Term Investments
Other Short-Term Assets	$1.210M	$299.0K	$299.0K
YoY Change	-52.53%	-32.51%	-32.51%
Inventory
Prepaid Expenses	$1.210M	$299.0K
Receivables
Other Receivables
Total Short-Term Assets	$1.785M	$3.060M	$3.060M
YoY Change	-77.21%	72.2%	72.2%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$8.742M	$8.742M	$8.742M
YoY Change	1.16%	173.1%	173.1%
Total Long-Term Assets	$8.742M	$8.742M	$8.742M
YoY Change	1.16%	173.1%	173.1%
TOTAL ASSETS
Total Short-Term Assets	$1.785M	$3.060M	$3.060M
Total Long-Term Assets	$8.742M	$8.742M	$8.742M
Total Assets	$10.53M	$11.80M	$11.80M
YoY Change	-36.1%	137.08%	137.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.506M	$9.939M	$9.939M
YoY Change	15.87%	246.91%	246.91%
Accrued Expenses	$979.0K	$1.379M	$1.379M
YoY Change	-28.17%	-53.93%	-58.44%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Long-Term Debt Due	$1.000M	$1.000M	$1.000M
YoY Change	0.0%	0.0%	0.0%
Total Short-Term Liabilities	$10.52M	$12.32M	$12.32M
YoY Change	7.93%	57.26%	57.26%
LONG-TERM LIABILITIES
Long-Term Debt	$3.194M	$4.194M	$4.194M
YoY Change	-23.84%	-19.25%	-19.25%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$3.194M	$4.194M	$4.194M
YoY Change	-23.84%	-19.25%	-19.25%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.52M	$12.32M	$12.32M
Total Long-Term Liabilities	$3.194M	$4.194M	$4.194M
Total Liabilities	$13.71M	$16.51M	$16.51M
YoY Change	-1.63%	26.75%	26.75%
SHAREHOLDERS EQUITY
Retained Earnings	-$132.6M	-$125.5M
YoY Change	37.86%	37.76%
Common Stock	$5.000K	$0.00
YoY Change	-68.75%	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.200M	-$4.710M	-$4.710M
YoY Change
Total Liabilities & Shareholders Equity	$10.53M	$11.80M	$11.80M
YoY Change	-36.1%	137.08%	137.08%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$7.100M	-$6.474M	-$25.26M
YoY Change	39.22%	36.73%	-27.61%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$9.400M	-$3.079M	-$25.25M
YoY Change	-4.08%	-38.48%	65.03%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00	$400.0K
YoY Change			-160.98%
Cash From Investing Activities		$0.00	$400.0K
YoY Change			-160.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$27.80M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$7.082M	4.752M	26.14M
YoY Change	-48.31%	-11.16%	388.27%
NET CHANGE
Cash From Operating Activities	-$9.400M	-3.079M	-25.25M
Cash From Investing Activities		0.000	400.0K
Cash From Financing Activities	$7.082M	4.752M	26.14M
Net Change In Cash	-$2.316M	1.673M	1.293M
YoY Change	-158.63%	386.34%	-112.22%
FREE CASH FLOW
Cash From Operating Activities	-$9.400M	-$3.079M	-$25.25M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2023	dei	Trading Symbol TradingSymbol	PBLA
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001029125
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	6003644	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4854861
CY2023	dei	Auditor Firm AuditorFirmId	677
CY2023	dei	Auditor Name AuditorName	Cherry Bekaert LLP
CY2023	dei	Auditor Location AuditorLocation	Tampa, Florida
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2578000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1285000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	299000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	443000	usd
CY2023Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	183000	usd
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	49000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	3060000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1777000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8742000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3201000	usd
CY2023Q4	us-gaap	Assets Assets	11802000	usd
CY2022Q4	us-gaap	Assets Assets	4978000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9939000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2865000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1141000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2993000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	238000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	325000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	650000	usd
CY2023Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1000000	usd
CY2022Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1000000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12318000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7833000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4194000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5194000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4194000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5194000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	16512000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	13027000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	480095
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1738
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	480025
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1738
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	70
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	1000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	-0	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	120043000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	82286000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-125497000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-91094000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	745000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	759000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-4710000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-8049000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11802000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4978000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5033000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6044000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20614000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28049000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-25647000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-34093000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	123000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	14000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	400000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	usd
CY2023	us-gaap	Interest Expense InterestExpense	317000	usd
CY2022	us-gaap	Interest Expense InterestExpense	288000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-682000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	198000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-956000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-34933000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25277000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-316.52
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-41341.21
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	108691
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	845
CY2021Q4	us-gaap	Shares Outstanding SharesOutstanding	10212
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	9605000	usd
CY2022	pbla	Stock Issued During Period Shares Exercise Of Warrants For Cash StockIssuedDuringPeriodSharesExerciseOfWarrantsForCash	4
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1088000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-34933000	usd
CY2022	pbla	Adjustments To Additional Paid In Capital Reverse Stock Split AdjustmentsToAdditionalPaidInCapitalReverseStockSplit	1000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	626000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-8049000	usd
CY2023	pbla	Stock Issued During Period Value Cashless Exercise Of Warrants StockIssuedDuringPeriodValueCashlessExerciseOfWarrants	0	usd
CY2023	pbla	Stock Issued During Period Value Exercise Of Warrants For Cash StockIssuedDuringPeriodValueExerciseOfWarrantsForCash	4749000	usd
CY2023	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	0	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	823000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-25263000	usd
CY2023	pbla	Adjustments To Additional Paid In Capital To Induce Warrant Exercise AdjustmentsToAdditionalPaidInCapitalToInduceWarrantExercise	0	usd
CY2023	pbla	Adjustments To Additional Paid In Capital Reverse Stock Split AdjustmentsToAdditionalPaidInCapitalReverseStockSplit	-9000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-14000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-4710000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-25263000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-34933000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	400000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-0	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	823000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1088000	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	238000	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	273000	usd
CY2023	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	132000	usd
CY2022	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-212000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-145000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	127000	usd
CY2023	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	5541000	usd
CY2022	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	2561000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7060000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2249000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2179000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	786000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25249000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15276000	usd
CY2023	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	400000	usd
CY2022	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	0	usd
CY2023	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	usd
CY2022	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	4000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	400000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-656000	usd
CY2023	pbla	Payments From Induced Exercise Of Warrants PaymentsFromInducedExerciseOfWarrants	359000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1650000	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	-0	usd
CY2023	pbla	Payments For Fractional Shares PaymentsForFractionalShares	10000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26142000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5354000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	0	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-4000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1293000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10582000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1285000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11867000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2578000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1285000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	404000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	15000	usd
CY2023	pbla	Noncash Adjustment For The Value Offered To Induce Warrants Exercise NoncashAdjustmentForTheValueOfferedToInduceWarrantsExercise	9140	usd
CY2022	pbla	Noncash Adjustment For The Value Offered To Induce Warrants Exercise NoncashAdjustmentForTheValueOfferedToInduceWarrantsExercise	0	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><b>2.</b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><b>Risks and Uncertainties</b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration in the United States, the Therapeutic Goods Administration in Australia, the European Medicines Agency in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may take many years, and is normally expected to involve substantial expenditure.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We have incurred losses of $125.5 million since our inception in 2011. For the year ended December 31, 2023, we incurred a net loss of $25.3 million. Not reflected in the net loss for the year ended December 31, 2023, was an adjustment to accumulated loss of $9.1 million associated with the cost to induce warrant exercises. We incurred negative cash flows from operating activities of approximately $25.2 million for this period. As we continue to pursue development activities and seek commercialization of our lead assets, we expect to incur substantial losses, which are likely to generate negative net cash flows from operating activities. As of December 31, 2023, we had cash of $2.6 million, negative working capital of $9.3 million (current assets less current liabilities), and stockholders’ deficit of $4.7 million. The Company’s principal sources of cash have historically included the issuance of equity securities and convertible debt.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The accompanying Consolidated Financial Statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business and do not include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties. Our ability to continue as a going concern, realize the carrying value of our assets and discharge our liabilities in the ordinary course of business is dependent upon a number of factors, including our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our ivospemin (SBP-101), eflornithine (CPP-1X) and eflornithine sachets (CPP-1X-S) product candidates in the United States, Australia, the European Union or other markets, and Flynpovi outside of North America and ultimately our ability to market and sell our product candidates. These factors, among others, raise substantial doubt about our ability to continue operations as a going concern. See Note 3 titled “Liquidity and Management Plans”.</p>
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-125500000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-25300000	usd
CY2023Q4	pbla	Accumulated Loss From Induced Warrant Exercises AccumulatedLossFromInducedWarrantExercises	9100000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25200000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2600000	usd
CY2023Q4	pbla	Working Capital WorkingCapital	-9300000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 9pt;"><b><i>Use of estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of Consolidated Financial Statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>Concentration of credit risk</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. Cash is deposited in demand accounts at commercial banks. At times, such deposits may be in excess of insured limits. As of December 31, 2023, $2.3 million of the Company’s cash was in excess of insured limits. The Company has not experienced any losses on its deposits of cash.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	2300000	usd
CY2023	pbla	Warrant Inducement Cost WarrantInducementCost	9100000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	346563
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1587
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>Reclassifications</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. Specifically, we reclassified $0.1 million of prepaid expenses from current to non-current as of December 31, 2022.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q4	pbla	Clinical Trial Related Liabilities Current ClinicalTrialRelatedLiabilitiesCurrent	290000	usd
CY2022Q4	pbla	Clinical Trial Related Liabilities Current ClinicalTrialRelatedLiabilitiesCurrent	1760000	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	420000	usd
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	550000	usd
CY2023Q4	pbla	Accrued Supplemental Unemployment Benefits Severance Benefits And Payroll Taxes Current AccruedSupplementalUnemploymentBenefitsSeveranceBenefitsAndPayrollTaxesCurrent	96000	usd
CY2022Q4	pbla	Accrued Supplemental Unemployment Benefits Severance Benefits And Payroll Taxes Current AccruedSupplementalUnemploymentBenefitsSeveranceBenefitsAndPayrollTaxesCurrent	448000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	166000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	147000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	169000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	88000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1141000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2993000	usd
CY2022Q4	pbla	License Agreement Milestone Payments Achievement LicenseAgreementMilestonePaymentsAchievement	90000	usd
CY2023Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	2000000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	128
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	12.39
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	346563
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	10000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	68000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	63
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	132059
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022	pbla	Sharebased Compensation Arrangement By Sharebased Payment Award Number Of Shares Available For Grant Grants In Period SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod	42
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6743.41
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	-0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	-0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6743.41
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	104
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	82655.77
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023	pbla	Sharebased Compensation Arrangement By Sharebased Payment Award Number Of Shares Available For Grant Grants In Period SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod	503
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	300
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	-0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	-0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	-0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	607
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14410.38
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	823000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1088000	usd
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	18
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	92061.33
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	42
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	26038.83
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	52
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	38865.69
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	1
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	26038.83
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	7
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	100525.71
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	503
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	269.8
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	83
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	7002.26
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	-0
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	427
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	604.69
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	607
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P8Y8M4D
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	14410.36
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	180
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P7Y4M6D
CY2023	pbla	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Common Stock Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsCommonStockFairValue	300
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	usd
CY2023Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	183000	usd
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	49000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	18487000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17564000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	352000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	338000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2023000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1928000	usd
CY2023Q4	pbla	Deferred Tax Assets Capitalized Research And Development Amortization DeferredTaxAssetsCapitalizedResearchAndDevelopmentAmortization	5444000	usd
CY2022Q4	pbla	Deferred Tax Assets Capitalized Research And Development Amortization DeferredTaxAssetsCapitalizedResearchAndDevelopmentAmortization	1921000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	26316000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	21819000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	26316000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21819000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	pbla	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0	pure
CY2022	pbla	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.1083	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0022	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0004	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0068	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0011	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2191	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1301	pure
CY2023	pbla	Effective Income Tax Rate Reconciliation Foreign Research Incentives Percent EffectiveIncomeTaxRateReconciliationForeignResearchIncentivesPercent	0.0071	pure
CY2022	pbla	Effective Income Tax Rate Reconciliation Foreign Research Incentives Percent EffectiveIncomeTaxRateReconciliationForeignResearchIncentivesPercent	0.0014	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0004	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0288	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0074	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0033	pure
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-186000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-116000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	pbla	Income Tax Expense Benefit Noncurrent IncomeTaxExpenseBenefitNoncurrent	0	usd
CY2022	pbla	Income Tax Expense Benefit Noncurrent IncomeTaxExpenseBenefitNoncurrent	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-186000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-116000	usd

Files In Submission

Name	View Source	Status
0001437749-24-009418-index-headers.html	Edgar Link	pending
0001437749-24-009418-index.html	Edgar Link	pending
0001437749-24-009418.txt	Edgar Link	pending
0001437749-24-009418-xbrl.zip	Edgar Link	pending
ex_642791.htm	Edgar Link	pending
ex_642792.htm	Edgar Link	pending
ex_642793.htm	Edgar Link	pending
ex_642794.htm	Edgar Link	pending
ex_642795.htm	Edgar Link	pending
ex_642796.htm	Edgar Link	pending
ex_644061.htm	Edgar Link	pending
ex_645010.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img01.jpg	Edgar Link	pending
img02.jpg	Edgar Link	pending
img03.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pbla-20231231.xsd	Edgar Link	pending
pbla20231231_10k.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pbla-20231231_cal.xml	Edgar Link	unprocessable
pbla-20231231_def.xml	Edgar Link	unprocessable
pbla-20231231_lab.xml	Edgar Link	unprocessable
pbla-20231231_pre.xml	Edgar Link	unprocessable
pbla20231231_10k_htm.xml	Edgar Link	completed
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PBLA
Panbela Therapeutics, Inc. Stock $pbla

2024 Q1 Form 10-K Financial Statement

#000143774924009418 Filed on March 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBLA Panbela Therapeutics, Inc. Stock $pbla

2024 Q1 Form 10-K Financial Statement

#000143774924009418 Filed on March 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBLA
Panbela Therapeutics, Inc. Stock $pbla